EIKON THERAPEUTICS INC (EIKN)
Health Care · Preclinical and clinical-stage biopharmaceuticals · NASDAQ
A clinical-stage biopharmaceutical company utilizing a proprietary technology platform to discover and develop a pipeline of novel therapeutic candidates.
What EIKON THERAPEUTICS INC does
Eikon Therapeutics is a preclinical and clinical-stage biopharmaceutical company developing a pipeline of product candidates across multiple therapeutic areas. The company is leveraging its technology platform to advance drug discovery and development, with named programs including EIK1001, EIK1003, EIK1004, EIK1005, EIK1006, and an ARv7 program. The company is advancing these candidates through preclinical studies and clinical trials with plans for regulatory filings and commercialization if approved.
Themes: drug discovery platform, clinical-stage biopharma
Fundamentals
- Price$11.39 as of 2026-08-21 close
- Market cap$617M as of 2026-08-21
- P/En/a earnings data not available
- ROE-114.8% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta1.97 as of 2026-08-24
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How EIKN compares in its sector
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How EIKON THERAPEUTICS INC looks technically
EIKON THERAPEUTICS INC (EIKN): a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 26, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 10 trading days ago (its momentum flipped positive). It made a new 20-day high about 3 trading days ago.
Trend
7
| Distance from the 200-day | not enough price history yet — needs 200 trading sessions | n/a |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $10.23 | $10.23 |
| 200-day moving average | not enough price history yet — needs 200 trading sessions | n/a |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 24 calendar days ago — the swings before that are what the structure reading is measured on | 24 sessions |
| Since the 50/200 cross | not enough price history yet — needs 200 trading sessions | n/a |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 26, with buyers in control | 25.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30) | 57.6 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($9.08 to $14.51) — its "stochastic" reading is 43 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 42.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 10 trading days ago (its momentum flipped positive) | 10 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $17.40 | $17.40 |
|---|---|---|
| From the 52-week high | it is 34.5% below its 52-week high (its highest price of the past year) | -34.5% |
| Above the 52-week low | it is 44.2% above its 52-week low (its lowest price of the past year) | +44.2% |
| Below the 52-week high | it is 34.5% below its highest point of the past year | 34.5% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day low about 51 trading days ago | 51 sessions |
| All-time high | its highest closing price on record is $17.40 (set on 2026-02-05) | $17.40 |
| Given back of the 52-week move | not available for this company yet | n/a |
| From the all-time high | it is 34.5% below its all-time high | -34.5% |
| Nearest price level | not enough price history yet — needs 252 trading sessions | n/a |
| All-time low | its lowest closing price on record is $7.90 (set on 2026-04-28) | $7.90 |
| Above the all-time low | it is 44.2% above its all-time low | +44.2% |
Volatility
4
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 79% of it) | 21st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.06 between its high and its low — about 9.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.06 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $8.36 and $11.84 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $8.36 – $10.10 – $11.84 |
| Typical daily range (% of price) | its price moves about 9.3% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 9.3% |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.40× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.8% since the prior reading | -0.8% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.1% |
|---|---|---|
| Open gap | it gapped 2.6% above the previous close 10 sessions ago and has not traded back through the level it left behind at 9.21 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.6% |
| Gap filled | a 9.6% gap up opened on 2026-08-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 1 session to close | 1 session ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 12.6 percentage points (the stock gained 14.9% while the market gained 2.3%) | +12.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 1.0 percentage points (the stock gained 2.1% while the market gained 3.1%) | -1.0% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 34.5 percentage points (the stock lost 23.5% while the market gained 11.1%) | -34.5% |
| vs market, 12 months | not available for this company yet | n/a |
Signal agreement
2
| Bullish technical signals | 4 of the 7 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a fresh 20-day high, MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 7 |
|---|---|---|
| Bearish technical signals | 1 of the 7 technical signals we can compute for it is currently in a bearish state: lagging the market over 6 months — these describe past price behaviour, not a forecast | 1 of 7 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 3.7% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 2.3% of the share price. | +3.7% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 3% below the average price paid since 2026-02-05, so the typical buyer over that stretch is under water. That average is $11.73 — a volume-weighted average of daily closes over 127 sessions, not a true tick-by-tick VWAP. | -2.9% |
|---|
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Broke out to a new 20-day high · in a strong, established uptrend (ADX) · Just filled a gap (5%+ closed in the last week) · Most volatile (6%+ typical daily range) · Trading above the Ichimoku cloud | Learn: adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.00 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$24.60 range $4.00 – $32.00; median $29.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for EIKN
- Consensus EPS estimate-$1.52 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Substantial reliance on the success of early-stage clinical and preclinical product candidates, which may fail to demonstrate efficacy or safety.","Need for significant additional capital to fund research, development, and potential commercialization, with no assurance of success or future profitability.","Material weakness in internal control over financial reporting requiring remediation."]
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
Cluster buying: 3 different insiders reported open-market purchases (SEC code P) of EIKN within a 30-day window between 2026-02-04 and 2026-02-06. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Most recent open-market transaction: 2026-02-06. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about EIKN's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding EIKN as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 7,506,359
- Reported value $79,417,278
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
EIKN had 4,875,396 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
EIKN had 9.00% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 19.96 days to cover at the same settlement.
- Reported short interest (shares) 4,875,396
- Short interest (% of shares outstanding) 9.00%
- Prior settlement (shares) 4,627,639
- Reported change 5.35%
- Days to cover (reported) 19.96
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Specific direct competitors not clearly identified in provided filing text
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Frequently asked questions
What does EIKON THERAPEUTICS INC (EIKN) do?
Eikon Therapeutics is a preclinical and clinical-stage biopharmaceutical company developing a pipeline of product candidates across multiple therapeutic areas. The company is leveraging its technology platform to advance drug discovery and development, with named programs including EIK1001, EIK1003, EIK1004, EIK1005, EIK1006, and an ARv7 program.
What sector is EIKON THERAPEUTICS INC (EIKN) in?
EIKON THERAPEUTICS INC (EIKN) is classified in the Health Care sector. Its industry is Preclinical and clinical-stage biopharmaceuticals. It trades on NASDAQ.
Who are EIKON THERAPEUTICS INC's (EIKN) competitors?
Notable peers of EIKON THERAPEUTICS INC (EIKN) include Specific direct competitors not clearly identified in provided filing text. This peer set is informational only — not financial advice.
Is EIKON THERAPEUTICS INC (EIKN) overbought or oversold right now?
EIKON THERAPEUTICS INC (EIKN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 58, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on EIKN come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.